Log in to save to my catalogue

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleu...

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleu...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2667792408

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

About this item

Full title

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2022-06, Vol.23 (6), p.758-767

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundTreatment options for malignant pleural mesothelioma are scarce. Tazemetostat, a selective oral enhancer of zeste homolog 2 (EZH2) inhibitor, has shown antitumour activity in several haematological cancers and solid tumours. We aimed to evaluate the anti-tumour activity and safety of tazemetostat in patients with measurable relapse...

Alternative Titles

Full title

EZH2 inhibitor tazemetostat in patients with relapsed or refractory, BAP1-inactivated malignant pleural mesothelioma: a multicentre, open-label, phase 2 study

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_miscellaneous_2667792408

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_miscellaneous_2667792408

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(22)00277-7

How to access this item